WO2015129812A1 - ステロイド剤投与で誘発される成長障害に対する医薬 - Google Patents
ステロイド剤投与で誘発される成長障害に対する医薬 Download PDFInfo
- Publication number
- WO2015129812A1 WO2015129812A1 PCT/JP2015/055650 JP2015055650W WO2015129812A1 WO 2015129812 A1 WO2015129812 A1 WO 2015129812A1 JP 2015055650 W JP2015055650 W JP 2015055650W WO 2015129812 A1 WO2015129812 A1 WO 2015129812A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- cnp
- peptide
- npr
- group
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention reduces growth disorders induced by administration of a steroid agent containing a natriuretic peptide receptor B (NPR-B) agonist represented by C-type natriuretic peptide (CNP) or CNP derivative as an active ingredient and / or Or, it relates to an improved medicine.
- NPR-B natriuretic peptide receptor B
- CNP C-type natriuretic peptide
- steroidal agent is a generic term for a drug containing a steroid hormone or a modified chemically synthesized product thereof, and in many cases, means a pharmaceutical compound containing a glucocorticoid or a modified chemically synthesized product thereof.
- Steroids have pharmacological actions such as anti-inflammatory action, immunosuppressive action, lymphocyte damage action, vasoconstriction action, bronchodilation action, etc., and are known to be dramatically effective against various diseases. On the other hand, treatment with steroids has been reported to have a risk of developing serious side effects.
- Non-Patent Document 1 Non-Patent Document 2
- steroids as described above is afraid of side effects and neglects to use as directed by the doctor, not only will the condition of the underlying disease be treated (rebound), but nausea
- so-called “steroid withdrawal syndrome” such as headache, malaise, and blood pressure reduction has been pointed out (Non-patent Document 3).
- Non-Patent Document 4 In children, in addition to these, there is a risk of growth failure due to long-term use of steroids. When treated with steroids for a long time in children, excessive glucocorticoids in the body prevent the production and secretion of growth hormone (GROWTH HORONE) and insulin-like growth factor (IGF-1). Or the sensitivity to these hormones may be reduced. As a result, the normal growth of the child is suppressed, so-called “growth disorder”, and it is diagnosed as a so-called “short stature” that is significantly shorter than the standard growth curve of a child of the same age. (Non-Patent Document 4).
- Non-Patent Document 5 Growth disorders induced by administration of steroids are at least partially recovered by discontinuing or reducing subsequent doses (Non-Patent Document 5), while the growth period of children is limited. If the epiphyseal growth plate closes for puberty, further growth can no longer be expected, regardless of the use of steroids. For this reason, continuous treatment with steroids is necessary due to serious life-threatening diseases in childhood, and sufficient growth over the lifetime of subjects who cannot discontinue medication or reduce the dose over a long period of time. However, there is a possibility of becoming short stature without expectation.
- the growth disorder caused by steroid treatment is reduced and / or without reducing the therapeutic effect of steroids and worsening side effects other than growth disorders. If there are drugs that can improve, or drugs that can promote the growth of children with short stature due to treatment with steroids and treat short stature, improvement in QOL over the lifetime of the subject can be expected. Furthermore, by reducing the risk of growth disorder, it becomes possible to treat a primary disease with a sufficient amount of a steroid, and as a result, it is expected to lead to an improvement in the treatment result for the primary disease.
- Non-Patent Document 6 prophylactic or therapeutic administration of growth disorders induced by steroid administration is not recommended from the viewpoint of risk and benefit.
- CNP C-type natriuretic peptide
- C-Type Natururitic ePeptide hereinafter referred to as CNP
- NPR-B guanylate cyclase
- NPR-B guanylate cyclase
- CNP acts on chondrocytes and plays an important role in bone growth (Non-Patent Document 7, Non-Patent Document 8, etc.).
- Non-patent Documents 9 and 10 Bone elongation is promoted by continuous intravenous administration of CNP-22 to liver-specific CNP transgenic mice or normal mice.
- early basic studies have reported effects on osteoblast expression and bone resorption in addition to cartilage tissue (Non-patent Documents 11 and 12).
- the growth plate becomes thicker due to the expansion of the proliferating chondrocyte layer and hypertrophic chondrocyte layer, and 2) the extracellular matrix of the proliferating chondrocyte layer increases.
- Non-patent Document 8 the expression of the differentiation traits of chondrocytes at each differentiation stage of the growth plate is promoted. Furthermore, the phenotype of the achondroplasia model mouse showing a short stature and limb long bone bone shortening expression system was rescued by mating with a cartilage-specific CNP transgenic mouse (Non-patent Document 8). Therefore, CNP is considered to be effective in improving cartilage dysfunction during development or growth and various symptoms associated therewith, and in particular, clinical application as a therapeutic agent for short stature including achondroplasia. Is expected (Non-patent Document 13).
- Non-patent Document 14 NTproCNP, a marker of endogenous CNP secretion, was measured in bones when dexamethasone or prednisolone was administered to children with acute lymphoblastic leukemia (2-9 years old) for therapeutic purposes. It can be a biomarker of toxicity (Non-patent Document 14).
- Non-patent Document 15 When dexamethasone is added to cultured mouse chondrocytes, the expression level of CNP increases, while the number of chondrocytes and the expression level of the GC-B receptor decrease (Non-patent Document 15). is there.
- endogenous CNP and NTproCNP concentrations can be an indicator of growth failure caused by treatment with steroids.
- bone metabolism markers that can originally serve as indicators of growth disorders, such as bone alkaline phosphatase, osteocalcin, type I collagen N-propeptide, and type I collagen C-propeptide.
- An object of the present invention is to provide a medicament for reducing and / or improving a growth disorder induced by administration of a steroid, and a medicament for treating short stature caused by a growth disorder induced by administration of a steroid. To do.
- the inventors of the present invention have confirmed that the growth disorders similar to those reported in humans are manifested by continuous subcutaneous administration of a medicinal dose of steroids to rats. Furthermore, the present inventors have found that a growth disorder caused by a steroid agent can be reduced and / or improved by coadministering a CNP derivative to a rat in which a growth disorder is caused by continuous subcutaneous administration of a steroid agent.
- the alleviation effect of CNP derivatives on growth disorders caused by steroids was clearly stronger than the same dose of growth hormone, an existing short stature treatment. Furthermore, it was confirmed that the effect of reducing and / or improving the growth disorder of CNP derivatives is not observed only in the growth disorder induced by a specific steroid.
- growth disorders already caused by administration of steroids can be alleviated by administration of CNP derivatives to treat short stature caused by growth disorders. Based on these findings, further studies have been made and the present invention has been completed.
- the present invention provides the following inventions.
- (1) Contains at least one natriuretic peptide receptor B (NPR-B) agonist as an active ingredient, characterized in that it is administered to a growing individual who needs continuous administration of a steroid A medicament for reducing and / or improving a growth disorder induced by administration of a steroid.
- the NPR-B agonist is C-type natriuretic peptide (CNP), an active fragment thereof, a variant thereof, a derivative thereof or a modification thereof, or an anti-NPR-B antibody Medicine.
- CNP C-type natriuretic peptide
- the NPR-B agonist is hCNP-22 (SEQ ID NO: 1), hCNP6-22 (amino acids 6 to 22 of SEQ ID NO: 1) or hCNP-53 (SEQ ID NO: 2), a variant thereof, or a derivative thereof Or a modified product thereof (2).
- At least one additional peptide selected from a peptide derived from an immunoglobulin Fc region, a serum albumin and a C-terminal partial peptide of ghrelin is an N-terminal, C-terminal or hCNP-22 or hCNP6-22,
- the modified product is characterized in that PEG or a similar hydrophilic polymer thereof is bonded to the N-terminus, C-terminus, or both of hCNP-22, hCNP6-22, or hCNP-53 ( The medicament according to any one of 2) to (4). (9) The medicament according to any one of (1) to (8), which is administered at the start or during the period of steroid therapy, and reduces and / or improves growth disorders. (10) It is administered for the treatment of short stature caused by a growth disorder induced by administration of a steroid during or after completion of steroid therapy (1) to (8) Any of the medicines.
- the NPR-B agonists of the present invention reduce and / or ameliorate growth disorders induced by administration of steroids and treat short stature resulting from the growth disorders. Furthermore, in the conventional steroid treatment, the NPR- of the present invention can be used for the steroid treatment for a child who has not been able to administer a sufficient dose or a period for which a therapeutic effect can be obtained due to the concern about the occurrence of the growth disorder.
- Combining B agonists makes it possible to adopt a dose or administration period in which a therapeutic effect by a steroid agent can be sufficiently obtained by reducing and / or improving a growth disorder induced by administration of a steroid agent. Can improve results.
- the first group ( ⁇ ) is a normal control group
- the second group ( ⁇ ) is a dexamethasone solution at a concentration of 0.5 mg / ml
- the third group ( ⁇ ) is a dexamethasone solution at a concentration of 1 mg / ml at 0.25 ⁇ l / ml.
- Continuous subcutaneous administration at a rate of hr for 28 days.
- FIG. 2 shows the distribution of femur length ( ⁇ is individual data, ⁇ ⁇ ⁇ is mean ⁇ standard deviation) after continuous subcutaneous administration of dexamethasone to 7-week-old male Crl: CD (SD) rats for 28 days. It is a graph.
- the first group ( ⁇ ) is a normal control group
- the second group ( ⁇ ) is a dexamethasone solution at a concentration of 0.5 mg / ml
- the third group ( ⁇ ) is a dexamethasone solution at a concentration of 1 mg / ml, 0.25 ⁇ l / hr.
- Data marked with “*” indicate that there was a significant difference from the normal control group (p ⁇ 0.05).
- 3 shows that a 4-week-old male Crl: WI (Wistar) rat was administered subcutaneously with a 0.67 mg / ml solution of dexamethasone at a rate of 0.25 ⁇ l / hr for 28 days (the period of the black bar below the graph).
- the continuous continuous subcutaneous administration of the CNP derivative (A) was started from the 14th day after the start of the administration when a clear growth disorder due to dexamethasone was confirmed, and continued for 28 days (the period of the gray bar below the graph).
- the first group ( ⁇ ) is a normal control group
- the second group ( ⁇ ) is a group administered with dexamethasone alone
- the third group ( ⁇ ) is a group administered with dexamethasone and a CNP derivative (A) in combination.
- the administration of dexamethasone was continued for 28 days, and the CNP derivative (A) was continuously administered subcutaneously for 28 days from the 14th day after the start of dexamethasone administration at a rate of 0.25 ⁇ l / hr.
- the first group ( ⁇ ) is a normal control group
- the second group ( ⁇ ) is a group administered with dexamethasone alone
- the third group ( ⁇ ) is a group administered with dexamethasone and a CNP derivative (A) in combination.
- the administration of dexamethasone was continued for 28 days, and the CNP derivative (A) was continuously administered subcutaneously for 28 days from the 14th day after the start of dexamethasone administration at a rate of 0.25 ⁇ l / hr.
- Data with “**” indicate that there was a significant difference (p ⁇ 0.01) from the control group (second group).
- FIG. 5 shows that a 4-week-old male Crl: WI (Wistar) rat was administered subcutaneously with a 0.67 mg / ml solution of dexamethasone at a rate of 0.25 ⁇ l / hr for 28 days, and the third group contained CNP.
- Derivative (A) and human growth hormone in group 4 growth plate tissue image at the end of the femur at the end of the test when combined subcutaneously administered once a day for 28 days (toluidine blue staining) Is shown.
- the normal group that was not administered was designated as group 1 and the dexamethasone-only administration group was designated as group 2.
- the proliferated cartilage layer is indicated by a white double arrow
- the enlarged cartilage layer is indicated by a gray double arrow.
- the present invention is induced by administration of a steroid and a medicament containing at least one natriuretic peptide receptor B (NPR-B) agonist as an active ingredient, which reduces and / or ameliorates growth disorders induced by administration of the steroid.
- the present invention relates to a medicament for treating short stature caused by a growth disorder.
- the “natriuretic peptide receptor B agonist” refers to a B-type natriuretic peptide receptor NPR-B (Natururitic Peptide Receptor-B, aka guanylate cyclase B (GC-B), hereinafter simply “NPR- A substance having an action of activating guanylate cyclase (hereinafter referred to as “NPR-B agonist activity”). In the present specification, it is simply referred to as “NPR”. Sometimes referred to as “-B agonist”.
- a typical NPR-B agonist includes, for example, C-type natriuretic peptide (CNP).
- the NPR-B agonist of the present invention is not particularly limited as long as it is a substance having NPR-B agonist activity, and CNP, an active fragment thereof, a mutant thereof, a derivative thereof and a modified thereof can be used. .
- CNP an active fragment thereof, a mutant thereof, a derivative thereof and a modified thereof
- even peptides and low molecular weight compounds that do not have structural commonality with CNP are included in the agonist of the present invention as long as they have NPR-B agonist activity.
- the CNP of the present invention includes human-derived CNP-22 consisting of 22 amino acids (hCNP-22: GLSKGCFGLK LDRIGSMSGL GC: SEQ ID NO: 1, which has a common amino acid sequence in mammals such as pigs and rats), human-derived CNP-53 (HCNP-53, amino acid sequence: DLRVDTKSRA AWARLLQEHP NARKYKGANK KGLSKGCFGL KLDLIGSMSG LGC: GID G4 GLS .
- a ring structure formed by a disulfide bond between two C residues contained in the sequence (for example, in hCNP-22, a disulfide bond is formed between position 6 and position C of SEQ ID NO: 1).
- Forming a ring structure is considered to be important for binding to NPR-B receptor and expression of activity (Furuya M et al., Biochem. Biophys. Res. Commun. (1992), 183, No.3, 964- 969, Silver MA, Curr. Opin.Nephrol. Hypertens. (2006), 15, 14-21, Caldrone A, Minerva Endocrinol. (2004), 29, 113-127.
- CNP6-22 (a peptide consisting of amino acids 6 to 22 of SEQ ID NO: 1), which is a peptide consisting only of a ring structure, and N of the ANP ring structure at the N-terminal and C-terminal of the ring structure, respectively. Even if the terminal and C-terminal sequences are added, it exhibits NPR-B agonist activity almost the same as that of hCNP-22, and it is active in peptides having mutations at 9-position L and 10-position K of hCNP-22.
- Attenuated peptide having a mutation at other sites for example, S at position 16 and M at position 17
- LKL LLL
- a peptide substituted at positions 9 to 11 of SEQ ID NO: 1 exhibits NPR-B agonist activity almost the same as hCNP-22.
- the amino acid sequence of the ring structure important for NPR-B agonist activity is CFGLKLDRIG -Xaa1 -Xaa2 -SGLGC (where Xaa1 represents S or A, Xaa2 represents M, F or E: SEQ ID NO: 5), and this arrangement is called “ring structure arrangement”.
- the “active fragment” of a peptide or protein having biological activity consists of a site related to the biological activity of the peptide or protein, and retains at least part of the biological activity of the peptide or protein.
- the active fragment of CNP in the present invention a peptide consisting of at least a part of the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and having NPR-B agonist activity can be used.
- a peptide comprising the above-mentioned ring structure sequence (amino acid sequence of SEQ ID NO: 5) can be mentioned, and specific examples thereof include hCNP6-22, amino acid sequence of SEQ ID NO: 1, 3 or 4 A peptide in which a part or all of the consecutive amino acids including position 1 are deleted in positions 1 to 5 of the above; a part or all of the consecutive amino acids including position 1 in positions 1 to 31 of the amino acid sequence of SEQ ID NO: 2 Examples thereof include, but are not limited to, a deficient peptide, and those having a ring structure sequence and having NPR-B agonist activity can be employed as an active fragment of the CNP of the present invention.
- the NPR-B agonist of the present invention the above-mentioned active fragment itself can be adopted, and a peptide (active fragment) in which one or more amino acids are added to the N-terminus, C-terminus or both of the active fragment. Can be employed as long as they retain the desired agonist activity.
- peptides include peptides obtained by adding sequences derived from the C-terminus and N-terminus of ANP to the N-terminus, C-terminus and both of hCNP6-22 (Furuya M et al., Biochem. Biophys. Res. Commune). And (1992), 183, No. 3, pp. 964-969).
- a "variant" of a peptide or protein having biological activity is one to several amino acid substitutions, deletions, insertions, and the like in one to several amino acid sequences of the peptide or protein. / Or means added (hereinafter referred to as “substitution etc.”) and retaining at least part of the biological activity of the peptide or protein. “Several places” are usually 3 places, preferably 2 places. “Several” is usually 10, preferably 5, more preferably 3, even more preferably 2. In the case of substitution at a plurality of locations, any one of substitution, deletion, insertion and addition may be used, or two or more may be combined.
- the amino acid to be substituted may be a naturally occurring amino acid, a modified product such as an acylated product thereof, or an artificially synthesized amino acid analog.
- the site to be substituted may be selected as long as a part of the activity of the original peptide or protein is retained, but the active site or receptor binding site of the original peptide or protein, Those other than the above are preferably substituted.
- one substituted at a desired site can be adopted.
- the ring structure sequence described above is retained, and at other sites.
- a substituted peptide can be mentioned.
- 1 to several amino acids are substituted at one or more desired positions in the amino acid sequences shown in SEQ ID NOs: 1 to 4.
- one to several amino acids are present at one to several positions in the amino acid other than the amino acid represented by SEQ ID NO: 5 in the amino acid sequence described in any of SEQ ID NOS: 1 to 4.
- one to several amino acids are substituted in any one to several positions of positions 1 to 5 of the amino acid sequence shown in SEQ ID NO: 1, 3 or 4 Alternatively, one to several amino acids are substituted at any one to several positions in positions 1 to 31 of the amino acid sequence shown in SEQ ID NO: 2.
- the above-described mutant itself can be employed, and a peptide (mutant derivative) in which one or more amino acids are added to the N-terminus, C-terminus, or both. However, it can be employed as long as it retains the desired agonist activity.
- CNP mutants include that peptides having mutations at positions 17 and 18 of hCNP-22 have the same NPR-B agonist activity as hCNP-22, A mutant derivative in which the N-terminal and C-terminal are replaced with an ANP-derived sequence also shows NPR-B agonist activity that is about 90% of the activity of hCNP-22, and a mutation occurs at any one of positions 9 to 11.
- a peptide having a mutation at both positions 10 and 11 has an NPR-B agonist activity of 40% or more of hCNP-22, etc. (Furuya M et al., Biochem. Biophys. Res. Commun., (1992), 183, No. 3, Pp. 964-969).
- NEP neutral endopeptidase
- the “derivative” of a peptide or protein having biological activity is a fusion peptide containing the amino acid sequence of the peptide or protein and further added with another peptide or protein, and the bioactive peptide or protein. It means a fusion peptide that retains at least part of the biological activity of a protein.
- a fusion peptide having at least a part of such biological activity is also referred to as a derivative of a physiologically active peptide.
- an additional peptide may be fused to one of the C-terminal or N-terminal of the original physiologically active peptide or protein, and the additional peptide is fused to both the C-terminal and N-terminal.
- the peptide to be added is not particularly limited, but a peptide having no physiological activity is preferable.
- the additional peptide may be directly bonded, or may be bonded via a linker sequence consisting of 1 to several amino acids. Various linker sequences are known, but those containing a large amount of G, S, etc. are often used.
- Examples of such an additional peptide include an Fc site of an immunoglobulin (preferably IgG), serum albumin, a C-terminal partial sequence of ghrelin, and the like.
- Examples of derivatives used as the NPR-B agonist of the present invention include CNP (preferably hCNP-22 or hCNP-53) derivatives, CNP active fragments (preferably hCNP6-22) derivatives, and the like. , Preferably a derivative of hCNP-22 or a derivative of hCNP6-22.
- CNP derivatives include, for example, various CNP derivatives disclosed in US Patent Publication US2010-305031 (corresponding International Patent Publication WO2009 / 142C307) (SEQ ID NOs: 109 and 110 in the US Patent Publication). 124 to 130, 157 and 158: SEQ ID NOs: 6 to 14)) in the sequence listing of the present specification.
- a derivative obtained by adding a partial sequence derived from the C-terminal side of ghrelin to a physiologically active peptide such as ANP, CNP, or motilin retention in blood was improved while maintaining the physiological activity of the original peptide. Has been reported.
- Wk-Xl-Y-Zm-Wn (where W is a basic amino acid such as Lys, Arg, etc.) derived from the C-terminus of ghrelin at either the N-terminus or C-terminus of CNP and both.
- Y may be an acidic amino acid such as Asp, Glu, etc.
- X and Z may be the same or different, and may be any amino acid except an acidic amino acid or a basic amino acid.
- 1 or 2 represents an integer
- l and m each independently represent a natural number of 0, 1 or 2.
- Such sequences are preferably RKESKK, RKDSKK, RKSEKK, RKSDKK, etc.)
- NPR-B agonist activity was retained and its blood half-life was prolonged.
- the CNP derivative (A) (SEQ ID NO: 13) and CNP derivative (C) (SEQ ID NO: 8) used in the examples of the present invention are both representative examples of the CNP derivative prepared in this publication. The descriptions in the publication are all included in the description of the present specification.
- the NPR-B agonist activity comparable to that of hCNP-22 was also retained in the peptides (derivatives of CNP active fragments) (Furuya M et al., Biochem. Biophys. Res. Commun., (1992), 183 volumes). , No. 3, pp. 964-969).
- CNP-22 of the present invention in the amino acid sequence of humanCNP-53 (SEQ ID NO: 2), a peptide comprising an amino acid sequence from which 1 to 30 amino acids continuous from the N-terminus are deleted, Specific examples include CNP-36 (amino acid numbers 18 to 53 of SEQ ID NO: 2).
- a derivative preferably 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 continuous from the N-terminus of hCNP-53 (SEQ ID NO: 2) , A peptide comprising an amino acid sequence from which 24 or 25 amino acids have been deleted, and more preferably hCNP-36 from which 17 consecutive amino acids have been deleted from the N-terminus of hCNP-53 (the amino acid number of SEQ ID NO: 2) A peptide having an amino acid sequence of 18 to 53).
- CNP derivatives and derivatives of CNP active fragments can be preferably used as the NPR-B agonist of the present invention. More preferably, in SEQ ID NO: 2, a derivative comprising an amino acid sequence from which 1 to 30 (less than 25, more preferably 20 or less) consecutive amino acids have been deleted from the N-terminus, or SEQ ID NO: Any one of 6 to 15, more preferably a CNP derivative (A) (SEQ ID NO: 13), a CNP derivative (C) (SEQ ID NO: 8), or a CNP derivative (B) (SEQ ID NO: 15). ).
- the “modified body” of a peptide or protein having biological activity is one in which one to several amino acids contained in the peptide or protein are modified by a chemical reaction with another chemical substance, In addition, it means one that retains at least a part of the biological activity of the peptide or protein.
- the site to be modified may be selected as long as it retains the activity of the original peptide or protein.
- the modification is preferably performed at a site other than the active site of the peptide or protein or the receptor binding site.
- modification for preventing cleavage by a degrading enzyme it is preferable that a portion that undergoes the cleavage is modified.
- the modified form of CNP may be modified at one or more desired positions in any one of the amino acid sequences of SEQ ID NOs: 1 to 4, but preferably In the amino acid sequence of any one of SEQ ID NOs: 1 to 4, the amino acid other than the amino acid shown in SEQ ID NO: 5 is modified at one to several positions, more preferably the amino acid of SEQ ID NO: 1, 3, or 4 It is modified at any one to several positions of positions 1 to 5 of the sequence.
- a modification that imparts resistance to cleavage by NEP it is known that cleavage is performed between 1-position C and 2-position F of SEQ ID NO: 5 in the ring structure contained in various CNP peptides. This bond can also be modified.
- CNP active fragments, mutants, and modified derivatives thereof are also included in the present invention.
- Such various modifications can also be used in the present invention as long as they retain NPR-B agonist activity.
- a method of adding a high molecular polymer (pharmacologically used) used in pharmaceutical technology such as polyethylene glycol (PEG), polyvinyl alcohol (PVA), etc.
- PEG polyethylene glycol
- PVA polyvinyl alcohol
- a method of adding a compound serving as a linker to a side chain amino group such as a K residue and binding it to another protein or the like is known, but is not limited thereto.
- Various methods can be employed.
- CNP CNP
- Cys6-Phe7 which is the cleavage site by NEP in hCNP-22, is —CH2-NH— or —C ( ⁇ O) —N (R) — (R is a methyl group, ethyl
- R is a methyl group, ethyl
- a plurality of modified compounds substituted with a pseudo peptide bond such as a group, a propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, etc.
- the ring structure is important for the binding of CNP and NPR-B receptor, especially in derivatives and modified products in which another sequence or substance is bound to the terminal part, the added peptide or modification affects the ring structure. It is highly expected to retain NPR-B agonist activity without inhibiting binding to the NPR-B receptor. This has been demonstrated by many documents mentioned above.
- CNP CNP
- active fragments thereof, mutants thereof, derivatives thereof and modifications thereof may be collected from natural cells or tissues, and were produced using genetic engineering and cell engineering techniques. It may be a product, a chemically synthesized product, or an enzyme treatment or a chemical treatment that modifies amino acid residues or removes part of the amino acid sequence. Such a substance can be appropriately produced according to a conventional method with reference to the description and cited documents in this specification.
- NPR-B agonist activity can be easily measured by a person skilled in the art by a conventionally known method. Specifically, a substance is added to cultured cells in which NPR-B (SugagS et al., Endocrinology (1992), Vol. 130, No. 1, pp. 229-239) is forcibly expressed, and the intracellular cGMP level is measured. Is possible.
- NPR-B Suddens syndrome et al., Endocrinology (1992), Vol. 130, No. 1, pp. 229-2309
- the fact that a part of NPR-B agonist activity is retained means that when the NPR-B agonist substance and CNP are measured side by side using the same test system and the NPR-B agonist activity is measured, the peak of cGMP increasing activity is observed.
- cGMP increasing activity peak exhibited by CNP is retained, preferably it is retained 30% or more, more preferably it is retained 50% or more, more preferably It means holding 70% or more. Moreover, even if the increase in activity is not large at the peak, those showing good results in activity duration and blood retention when administered to a living body can be used in the present invention.
- a compound having a structure common to that of a natriuretic peptide (for example, a low molecular weight compound) can be used as long as a low molecular weight compound is added to such an evaluation system and the cGMP production ability is improved. Even so, it can be used in the present invention as an NPR-B agonist.
- an antibody produced by immunizing an animal using a protein containing a ligand binding site of NPR-B as an antigen and having NPR-B agonist activity by the above-described method is a Can be implemented with normal knowledge.
- the anti-NPR-B antibody having NPR-B agonist activity prepared as described above can also be used as the NPR-B agonist of the present invention.
- the antibody used in this way can be prepared in various known forms such as an antibody produced by an immunoprotozoa, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, and a fully human antibody.
- Antibody fragments such as Fab and scFv produced based on these antibodies can also be used.
- NPR-B agonist of the present invention is CNP, an active fragment having a ring structure sequence thereof, a variant substituted in other than the ring structure sequence, derivatives or modifications thereof, more preferably hCNP-22, hCNP-53, hCNP6-22, derivatives thereof or modifications thereof, and even more preferably, hCNP-53, CNP derivative (A): CNP (1-22) Ghrelin (12-28, E17D, SEQ ID NO: 13), CNP derivative (B): Pro-Gly-CNP-37 (SEQ ID NO: 15), CNP derivative (C): CNP (1-22) Ghrelin (12-28, SEQ ID NO: 8) and Such partial peptides are exemplified. ⁇ Subject of administration>
- the NPR-B agonist of the present invention is administered to a growing individual in need of continuous administration of a steroid agent, thereby reducing and / or improving a growth disorder induced by administration of the steroid agent in the subject. It can be used as an active ingredient of a medicine for
- an individual in a growth phase in which continuous administration of a steroid is required refers to a dose that can cause a disease that can be treated with a steroid and that can suppress or inhibit bone growth in normal growth and / or Alternatively, it means a growth phase subject who is scheduled to be taking or is completing administration of a steroid during the administration period.
- the administration target of the medicament of the present invention is not particularly limited as long as it is a mammal, and examples thereof include humans, monkeys, dogs, cats, horses, etc., preferably humans.
- the term “growth period” means a period in which the growth plate is maintained without closing the epiphyseal line of the long bone of the subject.
- the medicament of the present invention reduces and / or improves growth disorders, its effects can be remarkably easily obtained when administered to a subject at a high growth rate.
- the “steroidal agent” is a drug containing, as an active ingredient, glucocorticoids or their related compounds that are used for the treatment of diseases in the medical field.
- Representative examples include drugs containing prednisolone, beclomethasone, betamethasone, fluticasone, dexamethasone, hydrocortisone and the like (Payne et al., Paediatr Respir Rev., (2001), 2, pp. 145-150, Pelia G et al. Written, Life Sci., (2003), Vol. 72, Vol. 14, No. 14, pages 1549-1561), but is not limited thereto.
- the form of the steroid of the present invention is not limited, such as oral preparations, injections, and external preparations.
- growth disorder induced by administration of a steroid means the whole occurrence and progression of the following events, and the phenotype expressed as a result thereof.
- Long-term use of steroids for growing subjects is associated with the risk of developing growth disorders.
- excessive glucocorticoids in the body prevent the production and secretion of growth hormone (GROWTH HORONE) and insulin-like growth factor (IGF-1) And sensitivity to these hormones may be reduced.
- a disease requiring treatment with a steroid for a relatively long period of time in a growing subject i.e., a subject to whom the medicament of the present invention can be administered, or a disease affected in the past, for example, , Asthma, atopic dermatitis, systemic lupus erythematosus, rheumatic fever, juvenile idiopathic arthritis, ulcerative colitis, Crohn's disease, myasthenia gravis, Guillain-Barre syndrome, pulmonary hemosiderosis, childhood IgA nephropathy, idiopathic thrombocytopenia Purulent purpura, autoimmune hemolytic anemia, aplastic anemia, acute lymphoblastic leukemia, congenital adrenal hyperplasia and the like.
- reducing means that at least one of the effects of suppressing the occurrence of the disorder, mitigating / delaying the progression of the disorder, reducing the degree of the disorder, etc.
- it means that a short stature that may occur as a result of growth disorder does not occur, or that the degree of short stature is expected to be alleviated.
- it is desirable to start administration of the medicament of the present invention immediately before the start of steroid treatment, simultaneously with the start of treatment, or during the treatment period, and at the end of steroid treatment or for a certain period thereof. It is preferable to administer continuously until after elapse.
- “improving” the growth disorder means that the growth rate in the administration subject is improved to the same or higher than the standard growth rate of the same age, and does not cause short stature in the progression of the growth disorder. That at least one of the following effects is manifested, such as restoring the resulting short stature, and restoring the resulting disordered state closer to normal after the end of the event that induces the disorder. This means that the height of the subject is brought close to the standard height range (of the individual) of the same age.
- the medicament of the present invention is a subject in a growth period that has been treated with a steroid agent for a certain period of time or who has completed the treatment and tends to be short or is short. Administration will begin for the subject. When administered during the period of steroid treatment, both a relief effect and an improvement effect are expected to appear.
- the medicament of the present invention reduces or / or ameliorates growth disorders induced by steroid administration in a subject in need of continuous administration of steroids, or is caused by growth disorders
- a drug containing the NPR-B agonist of the present invention as an active ingredient which is prescribed for the purpose of treating short stature
- steroid drug therapy is described in a document attached to the drug.
- Administration to a subject who is receiving it which may cause growth disorder due to administration of a steroid, or administration to a subject in which a growth disorder has occurred, and the pharmaceutical of the present invention reduces and / or improves the growth disorder Or administration for the purpose of treating or treating short stature resulting from the growth disorder.
- the medicament of the present invention is induced by administration of a steroid agent in the administration subject immediately before the start of steroid therapy, at the same time as or during the period, and continued during the period of steroid therapy. Growth disorders may be reduced and / or ameliorated, or short stature caused by growth disorders may be treated.
- the drug of the present invention is “continuously administered during the period of steroid therapy” means that the subject to be administered has all the active ingredients (steroid drug and Means that the NPR-B agonist) of the invention is taken into the body.
- a formulation containing all active ingredients in a single formulation may be administered, or each active ingredient may be formulated separately and all of them may be administered separately.
- the timing of administration is not particularly limited, and may be administered at the same time, and may be administered at different times or on different days.
- “administered in combination” of a plurality of active ingredients or drugs includes administration of a plurality of active substances acting as NPR-B agonists alone.
- the order of administration of the active ingredients is not particularly limited.
- the administration may be the same number of times or may be different times.
- the administration method (administration route) of each preparation may be the same, or may be administered by different administration methods (administration route).
- the medicament of the present invention can be treated during or after completion of steroid therapy, thereby treating short stature caused by a growth disorder induced by administration of the steroid.
- short stature generally refers to short stature when the stature is -2SD or less, or the growth rate for 2 years is -1.5SD or less, compared to the same-sex, same-age, Defined. Administration in this case is performed in a period in which the subject is in the growth phase and usually does not exceed the standard height + 2SD at the age of the subject.
- the risk of growth disorder due to steroid administration is reduced, so that it is possible to increase the amount of steroid used for the treatment of the primary disease or to extend the treatment period. Therefore, there is a possibility of improving the treatment outcome of the primary disease, and the present invention also provides such a drug.
- the substance that can be used as the active ingredient of the medicament of the present invention may be a pharmaceutically acceptable salt of the NPR-B agonist described above. That is, in the present invention, an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, or an organic acid such as formic acid, acetic acid, butyric acid, succinic acid, or citric acid is effectively used as the NPR-B agonist described above. It can also be used as an ingredient. Alternatively, in the present invention, metal salts such as sodium, potassium, lithium and calcium, and salts with organic bases of the above NPR-B agonist can be used as active ingredients.
- an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, or an organic acid such as formic acid, acetic acid, butyric acid, succinic acid, or citric acid
- metal salts such as sodium, potassium, lithium and calcium, and salts with organic bases of the above NPR-B agonist can be used as active ingredients.
- the pharmaceutical composition according to the present invention may be a free form of the substance relating to the active ingredient or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition of the present invention contains an NPR-B agonist or a pharmaceutically acceptable salt thereof as an active ingredient, and further includes carriers and excipients used in normal formulation, other additives, diluents, etc. It is prepared using.
- the carrier and excipient for the preparation include lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, gum arabic, olive oil, sesame oil, cocoa butter, ethylene glycol, and other commonly used ones. be able to.
- the solid composition for oral administration tablets, pills, capsules, powders, granules and the like are used.
- at least one active ingredient is at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, aluminate metasilicate.
- the composition comprises additives other than inert diluents according to conventional methods, for example lubricants such as magnesium stearate, disintegrants such as calcium calcium glycolate, solubilizing agents such as glutamic acid or aspartic acid May be included.
- the tablets or pills may be coated with a sugar coating such as sucrose, gelatin or hydroxypropylmethylcellulose phthalate or a film of a gastric or enteric substance, or may be coated with two or more layers. Also included are capsules of absorbable materials such as gelatin. *
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, commonly used inert diluents such as purified water. , Ethanol and the like may be contained.
- the composition may contain adjuvants such as wetting agents and suspending agents, sweeteners, flavors, fragrances, preservatives and the like.
- the injection for parenteral administration includes sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- aqueous solutions and suspensions include water for injection and physiological saline for injection.
- non-aqueous solution and suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, alcohols such as ethanol, polysorbate 80 (registered trademark), and the like.
- Such compositions may further contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers (eg lactose), solubilizers (eg glutamic acid, aspartic acid). .
- the injection may be a solution preparation or may be lyophilized for dissolution and reconstitution before use.
- a normal sterilization method such as filtration sterilization using a microfiltration membrane, heat sterilization such as high-pressure steam sterilization, or blending of a bactericide.
- the injection may be a solution preparation or may be lyophilized for dissolution and reconstitution before use.
- sugar alcohols and sugars such as mannitol and glucose can be used.
- the pharmaceutical composition of the present invention is administered by an administration method generally used in medicine, for example, an oral administration method or a parenteral administration method such as transmucosal administration, intravenous administration, intramuscular administration, or subcutaneous administration. Is preferred.
- an oral administration method or a parenteral administration method such as transmucosal administration, intravenous administration, intramuscular administration, or subcutaneous administration.
- the active ingredient is an NPR-B agonist antibody
- it is usually administered via a parenteral route, such as injection (subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, etc.), transdermal, transmucosal, nasal, transpulmonary.
- parenteral route such as injection (subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, etc.), transdermal, transmucosal, nasal, transpulmonary.
- oral administration is also possible.
- the active ingredient is a peptidic substance
- a ribosome such as a preparation that is not easily degraded in the digestive tract.
- the administration method which absorbs from mucous membranes other than digestive tracts, such as a rectum, a nose, and a sublingual is also possible. In this case, it can be administered to an individual in the form of a suppository, a nasal spray, an inhalant, or a sublingual tablet.
- the dose of a substance that can be used as an active ingredient of the pharmaceutical composition according to the present invention varies depending on the type of the primary disease, the age of the individual (subject), the body weight, the degree of symptoms, the route of administration, etc.
- the upper limit of the daily dose is, for example, about 100 mg / kg or less, preferably about 50 mg / kg or less, and more preferably 5 mg / kg or less.
- the lower limit of the daily dose is, for example, about 0.005 ⁇ g / kg or more, preferably 0.025 ⁇ g / kg or more, and more preferably 0.1 ⁇ g / kg or more.
- the dose of CNP of the present invention varies depending on the body weight, indication disease, symptoms, etc. of the subject individual, but is locally about 10 ⁇ 15 M to 10 ⁇ 6 M, preferably 10 ⁇ 12 M to 10 for local administration. -8 M. In systemic administration, it is about 0.01 ⁇ g / head to 10,000 ⁇ g / head, preferably 1 ⁇ g / head to 5000 ⁇ g / head.
- the pharmaceutical composition of the present invention is used in combination with a steroid agent or administered to a subject who has been administered a steroid agent in the past.
- the pharmaceutical composition of the present invention may be used in combination with other osteogenesis promoter, bone resorption inhibitor or therapeutic agent for short stature.
- combination drugs include bisphosphonate preparations, bone morphogenetic protein (BMP) preparations, parathyroid hormone (PTH) preparations, basic fibroblast growth factor (bFGF) preparations, anti-osteoclast differentiation Factor (RANKL) antibody preparations, growth hormone (GROWTH HORMONE) preparations, insulin-like growth factor (IGF-1) preparations and the like can be mentioned, but are not limited thereto.
- a viral vector preferably a lentiviral vector, an adeno-associated viral vector, more preferably an adenoviral vector, a chemically synthesized liposome, a viral envelope, or a viral envelope and a synthetic liposome.
- An NPR-B agonist peptide amino acid sequence is encoded downstream of a promoter sequence that functions in a host cell, such as a cytomegalovirus promoter (CMV promoter), in a known medium suitable for gene therapy, such as a complex of A nucleic acid incorporating the nucleic acid to be used can be used.
- CMV promoter cytomegalovirus promoter
- a gene encoding CNP a gene containing a nucleotide sequence encoding any amino acid sequence of SEQ ID NOs: 1 to 5 may be used.
- the method described in Experimental Medicine, Vol. 12, p. 303, 1994, or the method of literature cited therein may be used.
- CNP derivative (A) (SEQ ID NO: 13) and CNP derivative (C) (SEQ ID NO: 8) used in this example were prepared based on the description in US Patent Publication US2010-305031.
- CNP derivative (B) (SEQ ID NO: 15) was prepared based on the description in the pamphlet of WO2009 / 067639.
- Example 1> Preparation of dexamethasone-induced growth disorder model rat [Method] Dexamethasone at a concentration of 0.5 mg / ml (group 2) or 1 mg / ml (group 3) in an osmotic pump (MINI-OSMOTIC PUMP Model 2004, manufactured by DURECT, flow rate: 0.25 ⁇ l / hr, for 28 days) Dexamethasone injection “KS” (manufactured by Kyoritsu Pharmaceutical Co., Ltd.) was filled and implanted one by one under the skin of the back of 7-week-old male Crl: CD (SD) rats (5 animals / group, 10 animals in total).
- KS manufactured by Kyoritsu Pharmaceutical Co., Ltd.
- osmotic pumps (same as above) filled with physiological saline were implanted subcutaneously into the control group (first group, 5 animals) one by one. Thereafter, the animals were reared for 28 days, and their body weights were measured at a frequency of 2-3 times / week. On the final day, blood was lethal under isoflurane anesthesia, the right femur was removed, and the length was measured. The collected blood is made into plasma, then cholesterol E-Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.) is used to determine the cholesterol concentration, and Corticosterone, ELISA Kit, AssayMax (96well) (EC3001-1, manufactured by ASSAYPRO).
- FIG. 1 shows the weight transition of the rats during the dexamethasone administration period
- FIG. 2 shows the right femur length on the final day.
- Continuous subcutaneous administration of dexamethasone reduced body weight in a dose-dependent manner and shortened femur length in a dose-dependent manner.
- Table 1 shows the concentrations of corticosterone and cholesterol in the plasma collected on the last day.
- Example 2 Co-administration test of CNP derivative (A) for rat growth disorder induced by dexamethasone [Method] 1 mg / ml dexamethasone (dexamethasone injection “KS”, manufactured by Kyoritsu Pharmaceutical Co., Ltd., second group) and osmotic pump (MINI-OSMOTIC PUMP Model 2004, manufactured by DURECT, flow rate: 0.25 ⁇ l / hr, for 28 days) (Group 3) Or saline (Group 1) was filled as a control, and implanted subcutaneously in the back of 7-week-old male Crlj: WI (Wistar) rats one by one.
- the third group had a 20 mg / ml solution of the CNP derivative (A), the first group and the second group had medium 1 (0.03 mol / l acetate buffer (pH 4.0) / 1% benzyl alcohol.
- the osmotic pump (same as above) filled with / 10% purified sucrose) was implanted subcutaneously in the back at the same time as the pump containing dexamethasone or physiological saline. Thereafter, the animals were reared for 28 days.
- body weight, body length (length from the tip of the nose to the anus) and tail length were measured, blood was collected from the abdominal aorta under isoflurane anesthesia, and then the right femur and main tissues (spleen, thymus) , Liver, heart and lung).
- the bone length and width were measured using calipers, and the weight was measured for the main tissue.
- the collected blood is made into plasma and then cholesterol and IGF- using cholesterol E-test Wako (manufactured by Wako Pure Chemical Industries, Ltd.) and Quantikine® ELISA Mouse / Rat IGF-I Immunoassay (MG100, manufactured by R & D Systems). One concentration was measured.
- Table 3 shows the body weight, body length and tail length of the final day when dexamethasone and CNP derivative (A) were administered by continuous subcutaneous administration for 28 days, and Table 4 shows the length and thickness of the femur.
- the body weight on the final day was significantly lower in the second group and the third group administered with dexamethasone than in the first group (p ⁇ 0.01), and no effect of CNP derivative (A) combined administration was observed.
- body length, tail length, and femur length were significantly shortened with dexamethasone alone (Group 2) (p ⁇ 0.01), and combined with CNP derivative (A) (Group 3). It recovered to the same level.
- Table 5 shows the cholesterol concentration and IGF-1 concentration on the final day.
- the cholesterol concentration in plasma collected on the last day was significantly increased (p ⁇ 0.01) by dexamethasone alone (group 2).
- the third group showed variation among individuals, and there was no significant difference between the first group and the second group.
- Plasma IGF-1 concentrations were significantly lower in the second and third groups administered dexamethasone than in the first group (p ⁇ 0.05).
- Table 6 shows the main tissue weights on the final day.
- the spleen and thymus weights (weight ratio (%)) in the second and third groups administered with dexamethasone were significantly lower than those in the first group, and there was no effect of the combined administration of the CNP derivative (A). From these results, it was considered that the immunosuppressive effect of dexamethasone was not inhibited by the combined administration of the CNP derivative (A). As described above, it was shown that the suppression of bone elongation induced by dexamethasone administration (Group 2 and 3) is obviously improved by the combined administration of CNP derivative (Group 3).
- Example 3 Simultaneous combination administration test of human type CNP-53 or various CNP derivatives in dexamethasone-induced growth disorder model rats [Method] Fill the osmotic pump (MINI-OSMOTIC PUMP Model 2004, manufactured by DURECT, flow rate: 0.25 ⁇ l / hr, for 28 days) with dexamethasone (dexamethasone injection “KS”, manufactured by Kyoritsu Pharmaceutical Co., Ltd.) at a concentration of 0.67 mg / ml. Then, one male subcutaneous Crlj: WI (Wistar) rat (5 mice / group, 2nd to 6th group, 25 animals in total) was implanted subcutaneously in the back.
- WI Wistar
- the third group had a CNP derivative (A)
- the fourth group had a human CNP-53
- the fifth group had a CNP derivative (B)
- the sixth group had a CNP derivative (C) of 15 mg / kg.
- One osmotic pump (same as above) filled with ml solution was implanted subcutaneously in the back part one by one. None was administered to the normal control group (Group 1, 5 animals). Thereafter, the animals were reared for 28 days, and body weight, body length and tail length transition were measured.
- the femur length was significantly shortened by the administration of dexamethasone, and in the group (Groups 3 to 6) where human CNP-53, CNP derivative (A), (B) or (C) was administered in combination, There was a tendency to be longer than the group to which dexamethasone was administered alone (second group).
- the plasma cholesterol concentration and the thymus weight were the group administered with dexamethasone alone (second group) and the human CNP-53, CNP derivative (A), (B) or (C) No obvious difference was observed between (Group 3 to Group 6) (Table 8).
- Table 7 Body weight, height, tail length and right femur length at the end of administration when dexamethasone and various CNP derivatives were administered subcutaneously for 28 days to 5-week-old male Crlj: WI (Wistar) rats]
- CNP derivative (A) for dexamethasone-induced rat growth disorder [Method] Fill the osmotic pump (MINI-OSMOTIC PUMP Model 2004, manufactured by DURECT, flow rate: 0.25 ⁇ l / hr, for 28 days) with dexamethasone (dexamethasone injection “KS”, manufactured by Kyoritsu Pharmaceutical Co., Ltd.) at a concentration of 0.67 mg / ml. Then, 4 weeks old male Crlj: WI (Wistar) rats (5 mice / group, groups 2 and 3) were implanted one by one subcutaneously on the back and bred for 14 days.
- WI Wistar
- Example 5 Simultaneous administration of various steroids and CNP derivative (A) in rats [Method] Dexamethasone (dexamethasone injection “KS”, manufactured by Kyoritsu Pharmaceutical Co., Ltd., diluted with physiological saline) at a concentration of 0.3 mg / ml, prednisolone succinate suspended in saline containing 0.1% polysorbate (Wako Pure Chemical Industries, Ltd.) 4 mg, 5 mg / ml concentration as prednisolone) or betamethasone dipropionate suspended in 0.1% polysorbate-containing saline (manufactured by Wako Pure Chemical Industries, Ltd., 0.3 mg / ml concentration as betamethasone)
- Male Crlj: WI (Wistar) rats were subcutaneously administered to the back of 10 rats each at a volume of 1 mL / kg once a day for 28 days.
- CNP derivative (A) reduces and / or improves not only dexamethasone but also growth disorders induced by the administration of other steroids such as prednisolone and betamethasone.
- Table 10 Body weight, body length, tail length and right femur length after repeated subcutaneous administration of dexamethasone, prednisolone or betamethasone once daily for 28 days to male Crlj: WI (Wistar) rats]
- Example 6 Comparative test of CNP derivative (A) and human growth hormone against dexamethasone-induced rat growth disorder [Method] Fill the osmotic pump (MINI-OSMOTIC PUMP Model 2004, manufactured by DURECT, flow rate: 0.25 ⁇ l / hr, for 28 days) with dexamethasone (dexamethasone injection “KS”, manufactured by Kyoritsu Pharmaceutical Co., Ltd.) at a concentration of 0.67 mg / ml. Then, 4 weeks old male Crlj: WI (Wistar) rats (5 animals / group, 2nd to 4th groups, 15 animals in total) were implanted subcutaneously one by one.
- WI Wistar
- the third group contains a 1 mg / ml solution of the CNP derivative (A) (medium is 0.03 mol / l acetate buffer (pH 4.0) / 1% benzyl alcohol / 10% purified sucrose).
- a solution of human growth hormone preparation (somatropin BS subcutaneous injection 10 mg “sand”) diluted to 1 mg / ml with phosphate buffer was subcutaneously administered once a day at a volume of 2 mL / kg on the back of 5 rats. Administered for 1 day. None was administered to the normal control group (5 animals, 1 group).
- the body weight, body length and tail length were measured, blood was lethal from the abdominal aorta under isoflurane anesthesia, the left femur was removed, the bone length was measured, and a histopathological specimen at the end of the bone was prepared.
- Table 11 shows the body weight, body length, tail length, and left femur length when dexamethasone and CNP derivative (A) or human growth hormone were administered in combination.
- dexamethasone single administration group group 2
- body weight gain and body length and tail length elongation were significantly suppressed (p ⁇ 0.01).
- group (Group 3) administered with the CNP derivative (A) in combination the length and tail length elongation disorders were significantly improved as compared to the group (Group 2) administered dexamethasone alone (p ⁇ 0.01 and p ⁇ 0.05).
- the growth plate cartilage layer at the epiphysis of the left femur was narrowed by dexamethasone alone, and it was confirmed that the dexamethasone tends to be thickened by the combined administration of CNP derivative (A) or human growth hormone.
- FIG. 5 [Table 11: Weight, height, tail length and right femur length at the end of administration of dexamethasone subcutaneously for 28 days in 4-week-old male Crlj: WI (Wistar) rats and the CNP derivative (A) or Effects of repeated subcutaneous administration with human growth hormone
Abstract
Description
(1)ステロイド剤の継続的な投与が必要な成長期の個体に対して投与されることを特徴とする、少なくとも一種類のナトリウム利尿ペプチド受容体B(NPR-B)アゴニストを有効成分として含有する、ステロイド剤投与により誘発される成長障害を軽減及び/または改善するための医薬。
(2)NPR-Bアゴニストが、C型ナトリウム利尿ペプチド(CNP)、その活性断片、それらの変異体、それらの誘導体又はそれらの修飾体、或いは、抗NPR-B抗体である、(1)の医薬。
(3)NPR-Bアゴニストが、hCNP-22(配列番号1)、hCNP6-22(配列番号1のアミノ酸番号6乃至22)又はhCNP-53(配列番号2)、それらの変異体、それらの誘導体又はそれらの修飾体であることを特徴とする(2)の医薬。
(4)NPR-Bアゴニストが、hCNP-22またはhCNP6-22の誘導体又は修飾体であることを特徴とする(2)の医薬。
(5)誘導体が、免疫グロブリンFc部由来のペプチド、血清アルブミン及びグレリンのC末端側部分ペプチド、から選択される少なくとも一つの付加ペプチドが、hCNP-22またはhCNP6-22のN末端、C末端またはその両方に結合したペプチドであることを特徴とする(2)~(4)のいずれかの医薬。
(6)誘導体が、配列番号6乃至15から選択されるいずれかのアミノ酸配列からなるペプチドであることを特徴とする(2)~(5)のいずれかの医薬。
(7)誘導体が、配列番号8、13又は15のアミノ酸配列からなるペプチドであることを特徴とする(6)の医薬。
(8)修飾体が、PEGまたはその類縁物質親水性ポリマーが、hCNP-22、hCNP6-22、またはhCNP-53のN末端、C末端またはその両方に結合したものであることを特徴とする(2)~(4)のいずれかの医薬。
(9) ステロイド剤療法の開始時又は期間中に投与され、成長障害を軽減、及び/又は、改善することを特徴とする、(1)~(8)のいずれかの医薬。
(10) ステロイド剤療法の期間中又は終了後において、ステロイド剤投与で誘発された成長障害によって生じた低身長症の治療のために投与されることを特徴とする、(1)~(8)のいずれかの医薬。
<NPR-Bアゴニスト>
本発明におけるCNPとしては、22個のアミノ酸よりなるヒト由来CNP-22(hCNP-22:GLSKGCFGLK LDRIGSMSGL GC:配列番号1、ブタ及びラット等哺乳類では共通のアミノ酸配列を有する)、ヒト由来CNP-53(hCNP-53、アミノ酸配列:DLRVDTKSRA AWARLLQEHP NARKYKGANK KGLSKGCFGL KLDRIGSMSG LGC:配列番号2)、ニワトリ由来CNP-22(GLSRSCFGVK LDRIGSMSGL GC:配列番号3)、カエル由来CNP-22(GYSRGCFGVK LDRIGAFSGL GC:配列番号4)など、が挙げられる。
<投与対象>
<医薬の形態>
本発明の医薬組成物は、NPR-Bアゴニストまたはその薬学上許容される塩を有効成分として含み、さらに通常の製剤化の際に用いられる担体や賦形剤、その他の添加剤、希釈剤などを用いて調製される。製剤用の担体や賦形剤としては、例えば、乳糖、ステアリン酸マグネシウム、デンプン、タルク、ゼラチン、寒天、ペクチン、アラビアゴム、オリーブ油、ゴマ油、カカオバター、エチレングリコールなどやその他常用されるものをあげることができる。
<実施例1>:デキサメタゾン誘発成長障害モデルラットの作製
[方法]
浸透圧ポンプ(MINI-OSMOTIC PUMP Model2004、DURECT社製、流量:0.25μl/hr、28日用)に0.5mg/ml(第2群)または1mg/ml(第3群)濃度のデキサメタゾン(デキサメタゾン注「KS」、共立製薬株式会社製)を充填し、7週齢の雄性Crl:CD(SD)ラット(5匹/群、合計10匹)の背部皮下に1つずつ埋め込んだ。加えて、コントロール群(第1群、5匹)には、生理食塩水を充填した浸透圧ポンプ(同上) を背部皮下に1つずつ埋め込んだ。その後28日間飼育し、2-3回/週の頻度で体重を測定した。また、最終日には、イソフルラン麻酔下で採血致死させてから右大腿骨を摘出し、長さを測量した。採取した血液は血漿としたのち、コレステロールE-テストワコー(和光純薬工業株式会社製) を用いてコレステロール濃度を、及びCorticosterone、ELISA Kit、AssayMax(96well)(EC3001-1、ASSAYPRO社製)を用いて血漿中のコルチコステロン濃度をそれぞれ測定した。
[結果]
デキサメタゾン投与期間中のラットの体重推移を図1に、最終日の右大腿骨長を図2に示した。デキサメタゾンの持続皮下投与により、体重が用量依存的に低下すると共に大腿骨長が用量依存的に短縮した。また、最終日に採取した血漿中のコルチコステロン及びコレステロール濃度を表1に示した。デキサメタゾンの持続皮下投与により、第2群及び第3群においてコルチコステロン濃度が第1群と比べて有意に低下し、第3群においてはコルチコステロンの生合成に利用されるコレステロール濃度の上昇が認められた。
本試験において、デキサメタゾンの投与量は0.009~0.027mg/kg/日であり(表2)、デキサメタゾン注「KS」の添付文書に記載されている犬・猫への投与量(体重1kg当たりデキサメタゾンとして、0.05~0.1mgを1日1回皮下又は筋肉内に注射する)よりも低かった。デキサメタゾンは、ラットにおいても薬効用量で成長障害を誘発することを確認した。
[表1:雄性Crl:CD(SD)ラットにデキサメタゾンの28日間持続皮下投与終了時の血漿中コルチコステロン及びコレステロール濃度]
[方法]
浸透圧ポンプ(MINI-OSMOTIC PUMP Model2004、DURECT社製、流量:0.25μl/hr、28日用)に1mg/ml濃度のデキサメタゾン(デキサメタゾン注「KS」、共立製薬株式会社製、第2群及び第3群)または、コントロールとして生理食塩水(第1群)を充填し、7週齢の雄性Crlj:WI(Wistar)ラットの背部皮下に1つずつ埋め込んだ。その際、第3群にはCNP誘導体(A)の20mg/ml溶液、第1群及び第2群には媒体1(0.03 mol/l酢酸緩衝液(pH4.0)/1%ベンジルアルコール/10%精製白糖)を充填した浸透圧ポンプ(同上)を、デキサメタゾンまたは生理食塩水を含有したポンプと同時に背部皮下に1つずつ埋め込んだ。その後28日間飼育し、最終日に、体重、体長(鼻の先から肛門までの長さ)及び尾長を測定し、イソフルラン麻酔下で腹大動脈より採血後に、右大腿骨及び主要組織(脾臓、胸腺、肝臓、心臓及び肺)を摘出した。大腿骨については、ノギスを用いて骨長及び骨幅を測定し、主要組織については重量を測定した。採取した血液は血漿としたのち、コレステロールE-テストワコー(和光純薬工業株式会社製)及びQuantikine(R) ELISA Mouse/Rat IGF-I Immunoassay(MG100,R&D Systems製)を用いてコレステロール及びIGF-1濃度を測定した。
[結果]
デキサメタゾン及びCNP誘導体(A)を28日間持続皮下投与したときの最終日の体重、体長及び尾長を表3に、大腿骨の長さと太さを表4にそれぞれ示した。最終日の体重はデキサメタゾンを投与した第2群及び第3群で第1群よりも有意に低下し(p<0.01)、CNP誘導体(A)併用投与の影響は認められなかった。一方で、体長、尾長及び大腿骨長はデキサメタゾンの単独投与(第2群)で有意に短縮し (p<0.01)、CNP誘導体(A)の併用(第3群)で第1群と同レベルまで回復した。大腿骨幅に関しては、デキサメタゾン投与で短縮する傾向はあったが、有意差はなく(p>0.05)、CNP誘導体(A)の併用の影響も認められなかった。最終日のコレステロール濃度、IGF-1濃度を表5に示した。最終日に採取した血漿中のコレステロール濃度は、デキサメタゾンの単独投与(第2群)により有意に上昇した(p<0.01)。第3群は個体間でばらつきが認められ、第1及び第2群のどちらとも有意差はなかった。血漿中IGF-1濃度は、デキサメタゾンを投与した第2群及び第3群で第1群よりも有意に低下していた(p<0.05)。
最終日の主要組織重量を表6に示した。デキサメタゾンを投与した第2及び第3群の脾臓及び胸腺重量(体重比(%))は第1群と比べて有意に低下し、CNP誘導体(A)の併用投与の影響は認められなかったことから、デキサメタゾンの免疫抑制効果はCNP誘導体(A)の併用投与により阻害されないものと考えられた。
以上のように、デキサメタゾン投与(第2、3群)によって誘発された骨伸長抑制はCNP誘導体の併用投与(第3群)により明らかに改善することが示された。一方で、ラットにデキサメタゾンを投与すると、体重減少、血漿中コレステロール濃度上昇、IGF-1濃度低下、脾臓及び胸腺重量低下等の症状が観察されたが、それらについてCNP誘導体(A)を併用投与した影響は認められなかった。
[表3:雄性Crlj:WI(Wistar)ラットにデキサメタゾン及びCNP誘導体(A)を28日間持続皮下投与終了時の体重、体長及び尾長]
[方法]
浸透圧ポンプ(MINI-OSMOTIC PUMP Model2004、DURECT社製、流量:0.25μl/hr、28日用)に0.67mg/ml濃度のデキサメタゾン(デキサメタゾン注「KS」、共立製薬株式会社製)を充填し、5週齢の雄性Crlj:WI(Wistar)ラット(5匹/群、第2~第6群、計25匹)の背部皮下に1つずつ埋め込んだ。その際、第3群にはそれぞれCNP誘導体(A)、第4群にはヒト型CNP-53、第5群にはCNP誘導体(B)及び第6群にはCNP誘導体(C)の15mg/ml溶液を充填した浸透圧ポンプ(同上)をそれぞれ同時に背部皮下に1つずつ埋め込んだ。正常対照群(第1群、5匹)には、何も投与しなかった。その後、28日間飼育して体重、体長及び尾長推移を測定した。最終日に、イソフルラン麻酔下で腹大動脈より採血致死させ、採取した血液は血漿としたのちにラボアッセイTMコレステロール(和光純薬工業株式会社製)を用いてコレステロール濃度を測定した。また、採血致死後に右大腿骨及び胸腺を摘出し、右大腿骨長及び胸腺重量を測定した。
[結果]
デキサメタゾンの持続皮下投与と同時期に、ヒト型CNP-53、CNP誘導体(A)、(B)または(C)のいずれかを28日間併用持続皮下投与したときの最終日の体重、体長尾長及び大腿骨長を表7に示した。デキサメタゾンの単独投与群(第2群)では、ラットの体重の増加、並びに体長及び尾長の伸長が有意に抑制され、ヒト型CNP-53、CNP誘導体(A)、(B)または(C)のいずれかを併用投与した群(第3~第6群)では、デキサメタゾンを単独投与した群(第2群)と比べて体長及び尾長の伸長が有意に促進した(p<0.05または0.01)。大腿骨長はデキサメタゾンの投与で有意に短縮し、ヒト型CNP-53、CNP誘導体(A)、(B)または(C)のいずれかを併用投与した群(第3~第6群)では、デキサメタゾンを単独投与した群(第2群)よりも長くなる傾向が認められた。一方で血漿中コレステロール濃度や胸腺重量は、デキサメタゾンを単独投与した群(第2群)とヒト型CNP-53、CNP誘導体(A)、(B)または(C)のいずれかを併用投与した群(第3群~第6群)の間で、明らかな差は認められなかった(表8)。
[表7: 5週齢の雄性Crlj:WI(Wistar)ラットにデキサメタゾン及び各種CNP誘導体を28日間持続皮下投与したときの投与終了時の体重、身長、尾長及び右大腿骨長]
[方法]
浸透圧ポンプ(MINI-OSMOTIC PUMP Model2004、DURECT社製、流量:0.25μl/hr、28日用)に0.67mg/ml濃度のデキサメタゾン(デキサメタゾン注「KS」、共立製薬株式会社製)を充填し、4週齢の雄性Crlj:WI(Wistar)ラット(5匹/群、第2及び第3群)の背部皮下に1つずつ埋め込み、14日間飼育した。デキサメタゾンの投与により有意な矮小化(体重低下、体長及び尾長縮小)を確認した後に第3群のみにCNP誘導体(A)の15mg/ml溶液を充填した浸透圧ポンプ(同上)を追加で背部皮下に埋め込み、さらに28日間飼育した。飼育期間中の体重、体長及び尾長推移を測定するとともに、最終日に、イソフルラン麻酔下で腹大動脈より採血致死させて右大腿骨を摘出し、長さを測定した。
[結果]
試験期間中のラットの体重、体長及び尾長の推移を図3に示した。デキサメタゾンの投与開始14日後には、第1群と比べて第2群で有意な体重低下、体長及び尾長の縮小を観察した(表9)。その後、第3群のみでCNP誘導体(A)の投与を開始したところ、投与しない群(第2群)に比べて、体長及び尾長の伸びが大きくなり、CNP誘導体(A)投与開始28日後の体長及び尾長は、第3群で第2群よりも有意に長かった(p<0.01)。また、CNP誘導体(A)投与開始28日後の大腿骨も、併用しなかった群よりも有意に長く(p<0.01)(図4)、体重推移にはCNP誘導体(A)の併用投与による有意な変化は認められなかった。
[表9 デキサメタゾンの持続皮下投与により成長障害を誘発した雄性Crlj:WI(Wistar)ラットにCNP誘導体(A)を28日間持続皮下投与したときの体重、体長尾長及び大腿骨長]
[方法]
0.3mg/ml濃度のデキサメタゾン(デキサメタゾン注「KS」、共立製薬株式会社製を生理食塩水で希釈)、0.1%ポリソルベート含有食塩水に懸濁したこはく酸プレドニゾロン(和光純薬工業株式会社製、プレドニゾロンとして5mg/ml濃度)、または0.1%ポリソルベート含有食塩水に懸濁した二プロピオン酸ベタメタゾン(和光純薬工業株式会社製、ベタメタゾンとして0.3mg/ml濃度)を、4週齢の雄性Crlj:WI(Wistar)ラット 各10匹の背部皮下に1mL/kgの容量で1日1回28日間投与した。コントロール群(5匹、1群)には、何も投与しなかった。その際、各10匹のうち5匹(第2、第4、第6群)には、媒体(0.03 mol/l酢酸緩衝液(pH4.0)/1%ベンジルアルコール/10%精製白糖)を、残りの5匹(第3、第5、第7群)にはCNP誘導体(A)の1mg/ml溶液を背部皮下に1mL/kgの容量で1日1回28日間併用投与した。最終投与翌日にイソフルラン麻酔下で体重、体長及び尾長を測定後、腹大動脈より採血致死させ、右大腿骨を摘出し、大腿骨長を測定した。
[結果]
デキサメタゾン、プレドニゾロン及びベタメタゾンのいずれにおいても、28日間の反復投与により、ラットの体重の増加の有意な抑制、並びに体長、尾長及び大腿骨の伸長の有意な低下が観察された(p<0.05または0.01)(表10)ことより、これらのステロイド剤は、ラットにおいて成長障害を誘発するものと考えられた。これらのステロイド剤を反復投与したのと同じ時期にCNP誘導体(A)を1mg/kgの用量で併用反復皮下投与した結果、CNP誘導体(A)を投与しなかった群と比較して、体長、尾長及び大腿骨の有意な伸長が確認された(p<0.05または0.01)。これらのことから、CNP誘導体(A)はデキサメタゾンのみでなく、プレドニゾロンやベタメタゾンのような他のステロイド剤の投薬によって誘発された成長障害を軽減及び/又は改善することが示された。
[表10 雄性Crlj:WI(Wistar)ラットにデキサメタゾン、プレドニゾロンまたはベタメタゾンを一日1回28日間反復皮下投与した後の体重、体長、尾長及び右大腿骨長]
[方法]
浸透圧ポンプ(MINI-OSMOTIC PUMP Model2004、DURECT社製、流量:0.25μl/hr、28日用)に0.67mg/ml濃度のデキサメタゾン(デキサメタゾン注「KS」、共立製薬株式会社製)を充填し、4週齢の雄性Crlj:WI(Wistar)ラット(5匹/群、第2~第4群、計15匹)の背部皮下に1つずつ埋め込んだ。また、第3群にはCNP誘導体(A)の1mg/ml溶液(媒体は0.03 mol/l酢酸緩衝液(pH4.0)/1%ベンジルアルコール/10%精製白糖)を、第4群にはヒト型成長ホルモン製剤(ソマトロピンBS皮下注10mg「サンド」)をリン酸緩衝液で1mg/mlに希釈した溶液をラット 各5匹の背部皮下に2mL/kgの容量で1日1回28日間投与した。正常対照群(5匹、1群)には、何も投与しなかった。最終日に、体重、体長及び尾長を測定後、イソフルラン麻酔下で腹大動脈より採血致死させた後に左大腿骨を摘出して骨長を計測後、骨端部の病理組織標本を作製した。
デキサメタゾンとCNP誘導体(A)またはヒト型成長ホルモンを併用投与したときの体重、体長、尾長及び左大腿骨長を表11に示した。デキサメタゾンの単独投与群(第2群)では、体重の増加、並びに体長及び尾長の伸長が有意に抑制された(p<0.01)。CNP誘導体(A)を併用投与した群(第3群)では、デキサメタゾンを単独投与した群(第2群)と比べて、体長及び尾長の伸長障害が有意に改善した(p<0.01及びp<0.05)。ヒト型成長ホルモンを併用投与した群(第4群)では、デキサメタゾンを単独投与した群(第2群)と比べて体長及び尾長の伸長に有意な差は認められなかった(p>0.05)。最終日の左大腿骨長は、第1群と比較して、デキサメタゾンの投与(第2群)で有意に短く(p<0.01)、CNP誘導体(A)を併用投与した群(第3群)では、デキサメタゾンを単独投与した群(第2群)よりも有意に長かった(p<0.01)。ヒト型成長ホルモンを併用投与した群(第4群)とデキサメタゾンを単独投与した群(第2群)との間で有意差はなかった(p>0.05)。左大腿骨の骨端部の成長板軟骨層は、デキサメタゾンの単独投与により狭小化し、CNP誘導体(A)またはヒト型成長ホルモンの併用投与により、デキサメタゾンを単独投与時にくらべて肥厚する傾向が確認された(図5)。
[表11: 4週齢の雄性Crlj:WI(Wistar)ラットにデキサメタゾンを28日間持続皮下投与したときの投与終了時の体重、身長、尾長及び右大腿骨長とそれに対するCNP誘導体(A)またはヒト型成長ホルモン併用反復皮下投与の影響
Claims (10)
- ステロイド剤の継続的な投与が必要な成長期の個体に対して投与されることを特徴とする、少なくとも一種類のナトリウム利尿ペプチド受容体B(NPR-B)アゴニストを有効成分として含有する、ステロイド剤投与により誘発される成長障害を軽減及び/又は改善するための医薬。
- NPR-Bアゴニストが、C型ナトリウム利尿ペプチド(CNP)、その活性断片、それらの変異体、それらの誘導体又はそれらの修飾体、或いは、抗NPR-B抗体である、請求項1の医薬。
- NPR-Bアゴニストが、hCNP-22(配列番号1)、hCNP6-22(配列番号1のアミノ酸番号6乃至22)又はhCNP-53(配列番号2)、それらの変異体、それらの誘導体又はそれらの修飾体であることを特徴とする請求項1の医薬。
- NPR-Bアゴニストが、hCNP-22またはhCNP6-22の誘導体又は修飾体であることを特徴とする請求項1の医薬。
- 誘導体が、免疫グロブリンFc部由来のペプチド、血清アルブミン及びグレリンのC末端側部分ペプチド、から選択される少なくとも一つの付加ペプチドが、hCNP-22またはhCNP6-22のN末端、C末端またはその両方に結合したペプチドであることを特徴とする請求項2~4のいずれかの医薬。
- 誘導体が、配列番号6乃至15から選択されるいずれかのアミノ酸配列からなるペプチドであることを特徴とする請求項2~4のいずれかの医薬。
- 誘導体が、配列番号8、13又は15のアミノ酸配列からなるペプチドであることを特徴とする請求項6の医薬。
- 修飾体が、PEGまたはその類縁物質親水性ポリマーが、hCNP-22、hCNP6-22、またはhCNP-53のN末端、C末端またはその両方に結合したものであることを特徴とする請求項2~4のいずれかの医薬。
- ステロイド剤療法の開始時又は期間中に投与され、成長障害を軽減及び/又は改善することを特徴とする、請求項1~8のいずれかの医薬。
- ステロイド剤療法の期間中又は終了後において、ステロイド剤投与で誘発される成長障害によって生じた低身長症の治療のために投与されることを特徴とする、請求項1~8のいずれかの医薬。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167021444A KR20160118264A (ko) | 2014-02-27 | 2015-02-26 | 스테로이드제 투여로 유발되는 성장 장해에 대한 의약 |
CA2940835A CA2940835A1 (en) | 2014-02-27 | 2015-02-26 | Medicine against growth failure induced by administration of steroid |
EP15755876.8A EP3135296A4 (en) | 2014-02-27 | 2015-02-26 | Medicine against growth impairment induced by administration of steroid |
JP2016505298A JPWO2015129812A1 (ja) | 2014-02-27 | 2015-02-26 | ステロイド剤投与で誘発される成長障害に対する医薬 |
CN201580022391.XA CN106232141A (zh) | 2014-02-27 | 2015-02-26 | 针对由给予类固醇诱发的生长不足的药物 |
US15/122,011 US20170080049A1 (en) | 2014-02-27 | 2015-02-26 | Medicine against growth failure induced by administration of steroid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-036780 | 2014-02-27 | ||
JP2014036780 | 2014-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015129812A1 true WO2015129812A1 (ja) | 2015-09-03 |
Family
ID=54009126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/055650 WO2015129812A1 (ja) | 2014-02-27 | 2015-02-26 | ステロイド剤投与で誘発される成長障害に対する医薬 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20170080049A1 (ja) |
EP (1) | EP3135296A4 (ja) |
JP (1) | JPWO2015129812A1 (ja) |
KR (1) | KR20160118264A (ja) |
CN (1) | CN106232141A (ja) |
CA (1) | CA2940835A1 (ja) |
WO (1) | WO2015129812A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017118703A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
WO2017118704A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
WO2017118707A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
WO2017118700A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
WO2018060314A1 (en) * | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
WO2018139464A1 (ja) * | 2017-01-24 | 2018-08-02 | 第一三共株式会社 | 低身長症治療剤 |
US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
US11413351B2 (en) | 2016-01-08 | 2022-08-16 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with carrier attachment at the ring moiety |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094890A1 (ja) * | 2004-03-31 | 2005-10-13 | Kazuwa Nakao | 身長増加用組成物 |
WO2009142307A1 (ja) * | 2008-05-23 | 2009-11-26 | アスビオファーマ株式会社 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
JP2011504506A (ja) * | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | C型ナトリウム利尿ペプチドの変異体 |
WO2013161895A1 (ja) * | 2012-04-25 | 2013-10-31 | 第一三共株式会社 | 骨修復促進剤 |
-
2015
- 2015-02-26 CN CN201580022391.XA patent/CN106232141A/zh active Pending
- 2015-02-26 EP EP15755876.8A patent/EP3135296A4/en not_active Withdrawn
- 2015-02-26 CA CA2940835A patent/CA2940835A1/en not_active Abandoned
- 2015-02-26 US US15/122,011 patent/US20170080049A1/en not_active Abandoned
- 2015-02-26 JP JP2016505298A patent/JPWO2015129812A1/ja active Pending
- 2015-02-26 WO PCT/JP2015/055650 patent/WO2015129812A1/ja active Application Filing
- 2015-02-26 KR KR1020167021444A patent/KR20160118264A/ko unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094890A1 (ja) * | 2004-03-31 | 2005-10-13 | Kazuwa Nakao | 身長増加用組成物 |
JP2011504506A (ja) * | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | C型ナトリウム利尿ペプチドの変異体 |
WO2009142307A1 (ja) * | 2008-05-23 | 2009-11-26 | アスビオファーマ株式会社 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
WO2013161895A1 (ja) * | 2012-04-25 | 2013-10-31 | 第一三共株式会社 | 骨修復促進剤 |
Non-Patent Citations (3)
Title |
---|
HIROYUKI TANAKA: "Bone growth and glucocorticoid in children", KIDNEY AND METABOLIC BONE DISEASES, vol. 19, no. 2, 2006, pages 161 - 169, XP008185559 * |
HOCHBERG Z: "Mechanisms of steroid impairment of growth.", HORMONE RESEARCH, vol. 58, no. suppl 1, 2002, pages 33 - 38, XP008185218 * |
See also references of EP3135296A4 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL259829B (en) * | 2016-01-08 | 2022-11-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
WO2017118707A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
WO2017118700A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
AU2022202280B2 (en) * | 2016-01-08 | 2023-11-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
KR102518217B1 (ko) | 2016-01-08 | 2023-04-04 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
CN108472380A (zh) * | 2016-01-08 | 2018-08-31 | 阿森迪斯药物生长障碍股份有限公司 | 具有增加的nep稳定性的控制释放cnp激动剂 |
IL259829B2 (en) * | 2016-01-08 | 2023-03-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr–c binding |
US11413351B2 (en) | 2016-01-08 | 2022-08-16 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with carrier attachment at the ring moiety |
AU2017205273C1 (en) * | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
AU2017205273B2 (en) * | 2016-01-08 | 2022-06-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
WO2017118704A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
WO2017118703A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
US11154593B2 (en) | 2016-01-08 | 2021-10-26 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
US11224661B2 (en) | 2016-01-08 | 2022-01-18 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
CN108472380B (zh) * | 2016-01-08 | 2022-03-01 | 阿森迪斯药物生长障碍股份有限公司 | 具有增加的nep稳定性的控制释放cnp激动剂 |
KR20220035508A (ko) * | 2016-01-08 | 2022-03-22 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
AU2017205693B2 (en) * | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
US11389511B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
US11311604B2 (en) | 2016-01-08 | 2022-04-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
AU2017205694B2 (en) * | 2016-01-08 | 2022-05-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
US11389510B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
JP7189133B2 (ja) | 2016-09-29 | 2022-12-13 | アセンディス ファーマ グロース ディスオーダーズ エー/エス | 徐放cnp作動薬を用いた併用療法 |
EP4223309A1 (en) * | 2016-09-29 | 2023-08-09 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
IL290054B2 (en) * | 2016-09-29 | 2024-03-01 | Ascendis Pharma Growth Disorders As | Combined treatment with CNP agonists with controlled release |
JP2019535647A (ja) * | 2016-09-29 | 2019-12-12 | アセンディス ファーマ グロース ディスオーダーズ エー/エス | 徐放cnp作動薬を用いた併用療法 |
WO2018060314A1 (en) * | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
CN109843295A (zh) * | 2016-09-29 | 2019-06-04 | 阿森迪斯药物生长障碍股份有限公司 | 控释cnp激动剂的组合疗法 |
US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
AU2017336253B2 (en) * | 2016-09-29 | 2023-02-23 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
IL265592A (en) * | 2016-09-29 | 2019-05-30 | Ascendis Pharma Growth Disorders As | Combined therapy with CNP agonists with controlled release |
IL290054B1 (en) * | 2016-09-29 | 2023-11-01 | Ascendis Pharma Growth Disorders As | Combined treatment with CNP agonists with controlled release |
CN109843295B (zh) * | 2016-09-29 | 2022-04-05 | 阿森迪斯药物生长障碍股份有限公司 | 控释cnp激动剂的组合疗法 |
WO2018139464A1 (ja) * | 2017-01-24 | 2018-08-02 | 第一三共株式会社 | 低身長症治療剤 |
JPWO2018139464A1 (ja) * | 2017-01-24 | 2019-11-07 | 第一三共株式会社 | 低身長症治療剤 |
WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
Also Published As
Publication number | Publication date |
---|---|
CA2940835A1 (en) | 2015-09-03 |
US20170080049A1 (en) | 2017-03-23 |
CN106232141A (zh) | 2016-12-14 |
EP3135296A1 (en) | 2017-03-01 |
JPWO2015129812A1 (ja) | 2017-03-30 |
EP3135296A4 (en) | 2017-10-11 |
KR20160118264A (ko) | 2016-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015129812A1 (ja) | ステロイド剤投与で誘発される成長障害に対する医薬 | |
EP1265630B1 (en) | Use of insulin for the treatment of cartilagenous disorders | |
TWI471137B (zh) | C型利鈉胜肽變異體 | |
JP2004508410A (ja) | Glp−1及びglp−2ペプチドの使用方法 | |
JP2008545712A (ja) | ペプチド、その誘導体並びに類似体、及びそれらを使用する方法 | |
US20170121383A1 (en) | Therapeutic use of bone morphogenetic proteins | |
US20190314452A1 (en) | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins | |
JP2016506911A (ja) | 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤 | |
JP5948683B2 (ja) | 悪性腫瘍転移抑制用医薬 | |
US10781253B2 (en) | LEAP2 binding agents and compositions thereof | |
Grasso | Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs | |
JP6890340B2 (ja) | グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 | |
WO2017062693A1 (en) | Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies | |
JP6232630B2 (ja) | 骨系統疾患治療薬及びその用途 | |
US20160271265A1 (en) | Insulin-like growth factor mimetics for use in therapy | |
JP2016535015A (ja) | 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法 | |
WO2019201333A1 (zh) | Glp-1衍生物及其治疗用途 | |
TWI732713B (zh) | 人類生長激素融合蛋白gx-h9的用途 | |
JP6038795B2 (ja) | ナトリウム利尿ペプチド受容体gc−aアゴニスト及びgc−bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬 | |
WO2024027553A1 (zh) | 一种双功能融合蛋白及其用途 | |
RU2794170C2 (ru) | ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3) | |
US20150132344A1 (en) | Oral Leptin Formulations and Uses Thereof | |
WO2018139464A1 (ja) | 低身長症治療剤 | |
WO2022010996A1 (en) | Method and composition for reducing or preventing bone resorption | |
CN116685351A (zh) | Empacta的结果:一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15755876 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015755876 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015755876 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016505298 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167021444 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2940835 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15122011 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |